Pulmonx (LUNG) Cost of Revenue (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cost of Revenue data on file, last reported at $5.4 million in Q3 2025.

• Cost of Revenue for Q3 2025 came in at $5.4 million, up 1.66% year-over-year; the trailing twelve-month figure through Sep 2025 was $24.5 million (up 19.45% YoY), and the FY2024 annual result was $21.8 million, up 21.56% from the prior year.
• Cost of Revenue fell to $5.4 million in Q3 2025 per LUNG's latest filing, from $6.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.7 million in Q2 2025 and troughed at $500000.0 in Q4 2022.
• A 5-year average of $4.3 million and a median of $4.5 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 85.54% in 2022, then jumped 875.6% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $3.5 million in 2021, then plunged by 85.54% to $500000.0 in 2022, then jumped by 875.6% to $4.9 million in 2023, then rose by 26.59% to $6.2 million in 2024, then slipped by 11.74% to $5.4 million in 2025.
• Business Quant data shows LUNG's Cost of Revenue at $5.4 million in Q3 2025, $6.7 million in Q2 2025, and $6.2 million in Q1 2025.